AMENDMENT NO. 6 TO COLLABORATION AND OPTION AGREEMENTAnd Option Agreement • August 7th, 2013 • Cytokinetics Inc • Pharmaceutical preparations
This Amendment No. 6 to the Agreement (this “Amendment No. 6”) is entered into as of June 11, 2013 (the “Amendment Effective Date”) by and between Cytokinetics, Incorporated (“Cytokinetics”), a Delaware corporation, having its principal place of business at 280 East Grand Ave., South San Francisco, California 94080 and Amgen Inc., a Delaware corporation having its principal place of business at One Amgen Center Drive, Thousand Oaks, California 91320 (“Amgen”).
License and Collaboration Agreement by and between Cytokinetics, Inc. and Astellas Pharma Inc.License and Collaboration Agreement • August 7th, 2013 • Cytokinetics Inc • Pharmaceutical preparations
[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to rule 24b-2 of the Securities Exchange Act of 1934, as amended.
